Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and has made another move to further expand its influence.
It announced that it has signed an exclusive global collaboration deal with Biocon that should see the generics manufacture expand its biosimilar portfolio in the future.
Image caption:
IMAGE: Sandoz facility
